Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
Stocks in this Quantisnow insightHealth Care
Historical context for ABT
Across the 27 sessions after earlier ABT headlines, the stock closed higher 9 times and lower 18 times, with a median move of 1.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ABT | SPY |
|---|---|---|---|
| May 27, 2026 | ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening | -1.1% | -0.0% |
| May 26, 2026 | Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026 | -0.8% | +0.7% |
| Apr 28, 2026 | Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform | +1.1% | -0.5% |
| Apr 27, 2026 | Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 | +1.8% | +0.2% |
| Apr 22, 2026 | Abbott Labs downgraded by Daiwa Securities with a new price target | -1.1% | +1.0% |
| Apr 17, 2026 | New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test | +1.4% | +1.2% |
Quantisnow market dataNYSE
ABT
Abbott Laboratories
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ABT
Full ABT profile on Quantisnow Follow ABT and get a push notification the moment its next story breaks.